Tyra Biosciences Announces Participation at Upcoming Investor Events

Rhea-AI Summary

Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotech company specializing in Fibroblast Growth Factor Receptor (FGFR) precision medicines, has announced its participation in two upcoming investor events.

The company will participate in a fireside chat at the Virtual H.C. Wainwright "HCW@Home" series on August 21, 2025, at 11 AM ET. Additionally, management will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 9 AM ET in New York, featuring a fireside chat and one-on-one investor meetings.

Webcasts of both events will be accessible through Tyra's investor relations website.

CARLSBAD, Calif., Aug. 20, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that members of company management will participate in the following investor events:

          Virtual H.C. Wainwright "HCW@Home" series
          Format: Fireside chat
          Presentation Date/Time: Thursday, August 21, 2025, at 11 AM ET

          H.C. Wainwright 27^th Annual Global Investment Conference
          Format: Fireside chat and one-on-one investor meetings
          Presentation Date/Time: Wednesday, September 10, 2025, at 9 AM ET
          Location: New York, NY

A live webcast of the events can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. TYRA's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's expertise in FGFR biology has created a differentiated pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. TYRA's lead precision medicine stemming from SNÅP, dabogratinib, is a potential first-in-class selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for FGFR3 gatekeeper mutations. The current planned clinical development for dabogratinib includes SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia, and potentially future metastatic urothelial cancer studies. TYRA is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in the SURF431 study for advanced hepatocellular carcinoma, and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma. TYRA is based in Carlsbad, CA.

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:

Amy Conrad
aconrad@tyra.bio

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-announces-participation-at-upcoming-investor-events-302534890.html

SOURCE Tyra Biosciences

FAQ

When is Tyra Biosciences (TYRA) presenting at the H.C. Wainwright Global Investment Conference 2025?

Tyra Biosciences will present at the H.C. Wainwright Global Investment Conference on September 10, 2025, at 9 AM ET in New York, NY.

What type of presentations will TYRA give at the upcoming investor events?

TYRA will participate in fireside chat presentations at both the Virtual HCW@Home series and the H.C. Wainwright Global Investment Conference.

How can investors access Tyra Biosciences' (TYRA) upcoming investor presentations?

Investors can access the live webcasts through the 'For Investors' page on Tyra Biosciences' website. Recordings will be available for replay after the events.

What is Tyra Biosciences' (TYRA) main focus as a company?

Tyra Biosciences is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology.